NADAC acquisition cost data for TESTOSTERON CYP 1,000 MG/10 ML. This is a generic medication, typically more affordable than brand-name equivalents.
| NDC | NADAC/Unit | Effective Date | Type |
|---|---|---|---|
| 62756001740 | $3.55 | 2022-12-21 | Rx |
| 62756001740 | $3.55 | 2022-12-21 | Rx |
Generic: Testosterone | Manufacturer: Overall
| Year | Total Spending | Claims | Beneficiaries | Cost/Unit |
|---|---|---|---|---|
| 2019 | $118.1M | 290,610 | 88,490 | $2.82 |
| 2020 | $138.4M | 393,927 | 94,308 | $2.51 |
| 2021 | $124.8M | 424,112 | 99,523 | $2.07 |
| 2022 | $116.9M | 438,252 | 102,997 | $1.87 |
| 2023 | $117.0M | 494,459 | 116,916 | $1.71 |
| State | Total Cost | Claims | Beneficiaries |
|---|---|---|---|
| California | $16.5M | 76,973 | 18,179 |
| Florida | $9.0M | 39,288 | 10,196 |
| New York | $8.5M | 29,596 | 7,416 |
| Texas | $7.2M | 29,146 | 7,778 |
| Pennsylvania | $5.0M | 22,370 | 4,972 |
| Ohio | $4.4M | 15,915 | 3,994 |
| Massachusetts | $4.1M | 21,440 | 3,690 |
| North Carolina | $4.0M | 18,709 | 4,432 |
| Illinois | $3.7M | 13,185 | 3,250 |
| Georgia | $3.5M | 13,731 | 3,458 |
| New Jersey | $3.3M | 12,808 | 3,338 |
| Michigan | $3.0M | 12,926 | 3,330 |
| Arizona | $2.5M | 10,762 | 2,884 |
| Indiana | $2.5M | 9,699 | 2,342 |
| Tennessee | $2.4M | 10,505 | 2,598 |
| Washington | $2.4M | 9,833 | 2,470 |
| Virginia | $2.4M | 9,429 | 2,476 |
| Connecticut | $2.3M | 8,442 | 1,909 |
| Missouri | $2.3M | 9,817 | 2,334 |
| Maryland | $2.2M | 7,231 | 1,959 |
| Colorado | $2.1M | 9,884 | 2,395 |
| South Carolina | $2.0M | 10,021 | 2,471 |
| Wisconsin | $1.9M | 8,303 | 1,843 |
| Minnesota | $1.8M | 6,381 | 1,562 |
| Alabama | $1.8M | 7,067 | 1,655 |
| Oregon | $1.8M | 7,098 | 1,732 |
| Kentucky | $1.4M | 6,160 | 1,480 |
| Louisiana | $1.3M | 6,000 | 1,341 |
| Nevada | $963.8K | 4,016 | 1,091 |
| Oklahoma | $927.0K | 4,397 | 1,059 |
| Utah | $846.2K | 3,792 | 1,016 |
| Kansas | $841.1K | 3,665 | 886 |
| New Mexico | $750.2K | 3,364 | 748 |
| Idaho | $717.5K | 2,864 | 729 |
| Iowa | $686.7K | 2,992 | 693 |
| Maine | $576.4K | 2,547 | 619 |
| New Hampshire | $523.8K | 2,807 | 553 |
| Arkansas | $516.7K | 2,309 | 561 |
| Nebraska | $495.4K | 2,084 | 473 |
| Delaware | $488.6K | 1,746 | 441 |
| Rhode Island | $481.1K | 2,185 | 463 |
| West Virginia | $424.9K | 1,994 | 496 |
| Hawaii | $364.9K | 2,102 | 559 |
| Mississippi | $333.2K | 1,396 | 333 |
| District of Columbia | $314.9K | 1,034 | 290 |
| Alaska | $310.3K | 840 | 280 |
| Vermont | $287.9K | 1,214 | 287 |
| Puerto Rico | $245.5K | 1,100 | 242 |
| South Dakota | $224.0K | 966 | 228 |
| Montana | $212.5K | 1,063 | 274 |
| Wyoming | $114.9K | 497 | 130 |
| North Dakota | $112.4K | 604 | 148 |
The DrugPricePeek editorial team aggregates and verifies drugs data from CMS NADAC & Medicare Part D. Every statistic on this site is cross-referenced against the official source before publication, with quarterly re-verification cycles.
Read our full methodology or contact us with corrections.